Parkinson's Archives - Only Medics

August 31, 2017

AZ and Takeda join in $400m Parkinson’s therapy deal

AstraZeneca and Takeda have signed a deal to mutually develop and commercialise an experimental therapy for Parkinson’s disease. The companies will work together to advance AZ’ MEDI1341, an antibody to alpha-synuclein, an aggregation-prone protein that contributes to the development of the condition.

Written by Kat McCarthy

January 10, 2017

Allergan increases pipeline with Parkinson’s deal

Allergan has stepped into the field of Parkinson’s disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI). LTI-291, LTI’s lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many lysosomal storage diseases because of mutations in the GBA1 gene.

Only Medics

Recruiting Physicians for Pharma

Parkinson’s

AZ and Takeda join in $400m Parkinson’s therapy deal

Allergan increases pipeline with Parkinson’s deal

Like to Talk to a Consultant?